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with 44 mcg scIFNβ 1a in patients with EDSS > 3.5–5.0 was 1.21 per patient over 2 
years. The mean number of relapses avoided for the overall study population was 
0.74 per patient over 2 years. The average cost-effectiveness of 44 mcg scIFNβ 1a 
was estimated to be $107,861 per relapse avoided for the EDSS > 3.5–5.0 cohort. The 
average cost-effectiveness for the overall study population was estimated to be 
$181,208 per relapse avoided. Sensitivity analyses showed that results were robust 
to changes in key input parameters such as DMD costs, the number of relapses in 
untreated patients, the relative risk reduction in clinical relapse rates, the rate of 
adherence, and the average cost of relapse. ConClusions: Based on model results, 
the average cost-effectiveness of 44 mcg scIFNβ 1a was favorable for both the overall 
study population and the EDSS > 3.5–5.0 cohort.
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A Cost-Utility ANAlysis of sACrAl ANterior root stimUlAtioN (sArs) 
ComPAreD to meDiCAl treAtmeNt iN ComPlete sPiNAl CorD iNjUreD 
PAtieNts with A NeUrologiCAl BlADDer
Bénard A.1, Morlière C.1, Verpillot E.2, Donon L.1, Salmi L.R.1, Joseph P.A.1, Vignes J.R.1
1CHU Bordeaux, Bordeaux, France, 2Université de Bordeaux, Bordeaux, France
objeCtives: To estimate the cost-utility of sacral anterior root stimulation (SARS, 
using the Finetech-Brindley device) compared to medical treatment (anticholiner-
gics + catheterization) in complete spinal cord injured patients with a neurological 
bladder. Methods: A probabilistic Markov model was elaborated with a 10-year 
time-horizon, one-year cycles and a 2.5% discount rate. Three irreversible states 
were defined: 1) treatment without urinary complication; 2) surgery for urinary com-
plication (sphincterotomy, urinary derivation); 3) death. Reversible states (urinary 
calculi; Finetech-Brindley device failures) were integrated in the two first irreversible 
states. A systematic review and meta-analysis were performed to estimate transi-
tion probabilities and Quality Ajusted Life Years (QALYs). In the perspective of the 
French Healthcare System, costs were estimated from a published comparative 
cost-effectiveness research (Neurosurgery 2014; 73: 600), and through simulations 
using the 2013 French prospective payment system (PMSI) classification. Results: 
In the primary analysis, the cost-utility ratio was 10,647€ /QALY gained. At a 30,000€ 
ceiling ratio the probability of SARS being cost-effective compared to medical treat-
ment was 63%. If the French Healthcare System reimbursed SARS for 200 patients/
year the two first years and 50 patients/year during 8 years (anticipated target 
population) the expected incremental net health benefit would be 222 QALYs, and 
the expected value of perfect information (EVPI) would be 4,570,000€ . The highest 
partial EVPI is reached for transition probabilities toward urinary calculi (4,420,000€ ). 
With discount rates of 1% and 6% the cost-utility ratios were 6,951 and 19,770€ /
QALY gained, and the probabilities of SARS being cost-effective were 66% and 58%, 
respectively. ConClusions: Our model shows that SARS using Finetech-Brindley 
device offers the most important benefit and should be considered cost-effective 
at a 30,000€ ceiling ratio. Despite a high uncertainty, EVPI and partial EVPI may 
indicate that further research would not be profitable to inform decision making.
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ComPArisoN of A mArkov Cohort moDel AND A DisCrete-eveNt 
simUlAtioN for eCoNomiC ANAlyses of treAtmeNts for  
mUltiPle sClerosis
Kansal A.1, Tafazzoli A.1, Leipold R.1, Sarda S.2
1Evidera, Bethesda, MD, USA, 2Biogen Idec, Weston, MA, USA
objeCtives: Multiple sclerosis (MS) is a disease with lifelong impact, making the 
cost-effectiveness (CE) of its treatments particularly sensitive to assumptions 
embedded in model designs. Traditional sensitivity analysis (SA) can test many 
assumptions, but it is not designed to investigate sensitivity to structural assump-
tions. The aim of this study was to compare a Markov cohort model (MM) and a 
discrete-event simulation (DES) model of MS that were based on common clinical 
data but developed independently to understand the impact of their structural dif-
ferences on model predictions. Methods: A similar population was simulated in 
the MM and the DES model; aggregated cost and utility estimates were compared 
over varying time horizons. The average expanded disability status scale (EDSS) and 
the distribution of EDSS were also compared over time to study the dynamics of 
disease progression and treatment effects. Results: The two modeling approaches 
led to different natural history behavior over longer time horizons, even after short-
term behaviors were well-aligned, with the DES model predicting slightly fewer 
life-years (25.9 vs. 26.2 in the MM) but more quality-adjusted life-years (9.6 vs. 8.1 
in the MM). These differences reflect slower progression of EDSS in the DES model, 
particularly to higher EDSS states. When disease history (including a baseline EDSS 
term) was excluded from the DES model, the natural history simulations of the 
two models agreed more closely. ConClusions: Structural SA can help quantify 
the impact of key modeling decisions. In this study, a comparison of an MM and 
a DES model showed that natural history predictions diverge over long time hori-
zons, in part due to the consideration of disease history in the DES model. A better 
understanding of the differences between the two model designs helps ensure 
interpretation of the model results while taking into consideration the assumptions 
embedded in those designs.
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the loNg-term vAlUe of glAtirAmer ACetAte for the treAtmeNt of 
relAPsiNg remittiNg mUltiPle sClerosis iN the NetherlANDs
Wilson,L.E.1,2, Prüfert A.2
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objeCtives: To evaluate the cost-effectiveness of glatiramer acetate (Copaxone®) 
as a disease-modifying treatment (DMT) for relapsing-remitting multiple scle-
rosis (RRMS) compared to intravenous [natalizumab (Tysabri®), alemtuzumab 
(Lemtrada®) ] or subcutaneous injectables [interferon-beta-1b (Betaferon®), inter-
feron-beta-1a 44mcg, 22mcg, 30mcg (Rebif-44®, Rebif-22®, Avonex®) ] and oral DMTs 
[fingolimod (Gilenya®), dimethyl fumarate (Tecfidera®), teriflunomide (Aubagio®)].  
Methods: A Markov model followed patients over 50 years through 21 health 
and secondary analysis, respectively. Extensive sensitivity analyses indicated that 
results were robust. The most influential parameters were the utility estimates, 
probability of hospitalization per seizure and unit cost of hospitalization. The BIA 
showed that the annual cost of treating uncontrolled epileptic patients with LCM 
in Greece ranges between € 274.9 and € 271.5 million, in the primary and secondary 
analyses, respectively, compared to the respective costs with standard AED (€ 277.3 
and € 279.9 million). ConClusions: LCM appears to be both less costly and more 
effective compared with standard AED treatment in Greece and results in cost sav-
ings ranging between € 2.4 and € 8.3 million. Study funded by UCB Pharma.
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Cost-effeCtiveNess of sUBCUtANeoUs versUs iNtrAmUsCUlAr 
iNterferoN BetA-1A iN PortUgAl BAseD oN the fiNDiNgs of CoChrANe 
CollABorAtioN review of first-liNe treAtmeNts for relAPsiNg-
remittiNg mUltiPle sClerosis
Silverio N.1, Sequeira L.1, Meletiche D.2
1Merck SA, Alges, Portugal, 2EMD Serono, rockland, ME, USA
objeCtives: To estimate the cost-effectiveness of Interferon beta-1a subcutane-
ous (SC) when compared with Interferon beta-1a intramuscular (IM) in Portugal, 
based on the findings published by the Cochrane review of first-line treatments for 
relapse-remitting multiple sclerosis. Methods: An Excel-based model estimated 
the number of relapses and costs incurred by a cohort of 3,000 patients treated 
with two types of interferon beta-1a. The model evaluated the consequences of 
each treatment based on the findings of a Cochrane meta-analysis (Filippini 2013). 
The analysis was performed from a Portuguese NHS perspective, including only 
direct costs. Costs of relapse were obtained from a local publication (Mateus C, 
2000) whereas costs of both drugs were obtained from local official databases (Cat@
logo). Although efficacy was kept constant as Cochrane did not report outcomes 
based on EDSS, costs of relapse were available for patients with different EDSS 
values, thus allowing estimation of cost-effectiveness for different types of popu-
lation. Results: According to the model, over a 2 year period and in a population 
with EDSS ≤ 3, treatment with IM interferon beta-1a will result in a total of 2,228 
relapses, and a total cost of 69,572,717€ , whereas treatment with SC interferon beta-
1a will result in 1,709 relapses and a total cost of 70,480,835€ . For a population with 
EDSS between 3.5 and 4.5 cost values for IM and SC are 72,141,975€ and 72,451,135€ , 
respectively. Cost-effectiveness ratios were 1,748€ per relapse avoided when EDSS ≤ 
3 and 595€ per relapse avoided when EDSS was between 3.5 and 4.5. ConClusions: 
Considering that the cost of a relapse varies between 3,896€ (EDSS ≤ 3) and 5,139€ 
(EDSS between 3.5 and 4.5) the incremental cost-effectiveness ratios found for 
interferon beta-1a SC seem to indicate that that SC interferon beta-1a is a cost-
effective alternative to the use of IM interferon beta-1a.
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treAtiNg versUs NoN-treAtiNg oBstUriCtive sleeP APNeA iN itAly AND 
frANCe: A mArkov moDel-BAseD Cost-effeCtiveNess ANAlysis
Whitehouse J.T.1, Da Deppo L.2, Lazzaro C.3, Pedretti R.F.E.4, La Rovere M.T.5, Pepin J.L.6,  
Defaye P.6
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Sanitaria, Milan, Italy, 4IRCCS Fondazione Salvatore Maugeri Tradate, Tradate Milano, Italy, 
5IRCCS Fondazione Salvatore Maugeri Montescano, Montescano, Italy, 6Université Grenoble Alpes, 
Grenoble, France
objeCtives: To investigate the cost-effectiveness of treating vs. not treating 
obstructive sleep apnea (OSA) in Italy and France Methods: A 5-year, 10-state 
Markov model with disease states including; disease and event-free with OSA, dia-
betes, hypertension, myocardial infarction [MI], post-MI, stroke, post-stroke, atrial 
fibrillation [AF], heart failure [HF], and death; was developed to compare costs, out-
comes, and event-free life-years (LYS) of treating vs not treating OSA from the Italian 
National Health Service (INHS) and French National Health System (FNSH) view-
point. Health care resources included those related to diagnosis, treatment (CPAP 
only) and follow-up of OSA; management of hypertension, diabetes, HT, AF, post MI, 
and post-stroke (per year); MI, and stroke (per episode). Health care resources were 
valued at Euro (€ ) 2012 using published sources. Results: After 5 years the number 
of incremental event-free LYS per patient treated for OSA reaches 0.31 (Italy: 4.15 
vs 3.84; France: 4.07 vs 3.76). Treating OSA incurs an incremental cost of € 1011.01 
and € 2998.45per patient for Italy and France, respectively. The ICER of treating OSA 
is € 3212.39 for Italy and € 9777.09 for France, respectively. ConClusions: Treating 
OSA can be considered highly cost-effective for both the INHS and the FNSH when 
compared to the acceptability range for incremental cost effectiveness proposed 
for Italy (€ 25,000-€ 40,000) and for Europe (€ 50,000).
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Cost-effeCtiveNess of sUBCUtANeoUs iNterferoN BetA-1A iN A sUB-
PoPUlAtioN of mUltiPle sClerosis PAtieNts (kUrtzke exPANDeD 
DisABility stAtUs sCAle [eDss]: > 3.5–5.0)
Phillips A.L.1, Edwards N.C.2, Locklear J.C.1
1EMD Serono, Inc., Rockland, MA, USA, 2Health Services Consulting Corporation, Boxborough, 
MA, USA
objeCtives: To evaluate the cost-effectiveness of 44 mcg subcutaneous interferon 
beta-1a (scIFNβ 1a) in patients with multiple sclerosis (MS) with Kurtzke Expanded 
Disability Status Scale (EDSS) score > 3.5–5.0. Methods: The analysis was per-
formed from a US payer perspective. The time horizon of the analysis was 2 years. 
The decision analytic model was populated with real-world inputs and related 
assumptions, as well as pivotal placebo-controlled clinical trial data for 44 mcg 
scIFNβ 1a 3 times a week (PRISMS Study). Clinical inputs were obtained for the overall 
study population as well as a subpopulation of patients with Kurtzke EDSS score 
> 3.5–5.0. Disease-modifying drug (DMD) cost was based on 2014 wholesale average 
cost with consideration of patient copayment in the base case. Sensitivity analyses 
were conducted on key input variables to assess their impact on cost per relapse 
avoided. Results: Model results showed that the mean number of relapses avoided 
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objeCtives: Health care resource utilization and costs were evaluated for patients 
diagnosed with multiple sclerosis (MS) in the U. S. Medicaid program. Methods: 
Patients diagnosed with MS (International Classification of Disease, 9thRevision, 
Clinical Modification [ICD-9-CM] diagnosis code 340) were identified using Medicaid 
data from 01JAN2008 through 31DEC2010. The initial diagnosis date was designated 
as the index date. Patients of the same age, race, and gender but without an MS 
diagnosis were identified and matched as the comparison cohort, with a randomly 
chosen index date to minimize selection bias. Patients in both groups were required 
to be at least age 18 years, and have continuous medical and pharmacy benefits 
1 year before and 1 year post-index date. One-to-one propensity score matching 
(PSM) was used to compare health care costs and utilizations during the follow-up 
period, between the diseased and the comparison cohorts, and adjusted for baseline 
demographic and clinical characteristics. Results: After risk adjustment by PSM, a 
total of 14,179 patients in each cohort were matched. Significantly more MS patients 
had inpatient admissions (23.75% vs. 10.87%, p< 0.0001) and long-term care (22.64% 
vs. 4.13%, p< 0.0001), other service (99.70% vs. 89.00%, p< 0.0001) and pharmacy visits 
(73.08% vs. 67.71%, p< 0.0001) compared to those without an MS diagnosis. Higher 
health care utilization by MS patients led to significantly higher inpatient ($1,688 
vs. $725, p< 0.0001), long-term care ($14,189 vs. $2,778, p< 0.0001), other service visit 
($22,981 vs. $9,977, p< 0.0001) and pharmacy costs ($5,284 vs. $1,785, p< 0.0001) com-
pared to those without MS. ConClusions: Compared to patients in the comparator 
cohort, MS patients in the Medicaid program incurred substantially higher health 
care resource utilization and costs.
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Cost-Utility ANAlysis (CUA) of first-liNe DiseAse-moDifyiNg 
treAtmeNts (Dmt) versUs Best sUPPortive CAre (BsC) iN fiNNish 
relAPsiNg-remittiNg mUltiPle sClerosis (rrms) PAtieNts
Soini E.1, Asseburg C.1, Sumelahti M.L.2
1ESiOR Oy, Kuopio, Finland, 2School of Medicine, University of Tampere, Finland
objeCtives: CUA of teriflunomide and first-line DMTs (glatiramer acetate (GA), 
interferon-β -1a (IFNβ -1a: intramuscular IM, or subcutaneous SC) or interferon-β -1b 
(IFNβ -1b)), compared to BSC in Finnish RRMS-patients. Methods: Register study 
and Markov cohort modelling. During the 50-year time horizon, patients could stay 
or progress to another Expanded Disability Status Scale (EDSS) state, experience 
relapse (with/without hospitalisation), adverse events (AEs) or death. EQ-5D utili-
ties were derived from literature, and Finnish costs (health care 2013; official drug 
costs 4/2014 without VAT) were associated with EDSS, relapses, and AEs. Indirect 
treatment comparison informed treatment effects. EDSS-related standardised mor-
tality ratios (SMR) and RRMS-progression were analysed from Finnish MS-register 
(Tampere, Vaasa, Seinäjoki regions; 1359 patients). Other health risks were based 
on literature. Cohort characteristics were estimated from a subgroup (713 patients, 
clinically confirmed RRMS, age, gender and EDSS 0–6.5 at first DMT initiation). 
Caregiver’s disutility, Finnish productivity losses, and informal care costs were 
included in sensitivity analysis (societal perspective). Costs and quality-adjusted 
life-years (QALYs) were discounted with 3%/year. Results: Expected lifetime health 
care [societal] costs per patient were: teriflunomide: € 798,864 [€ 1,596,570], IFNβ -1a-
SC: € 805,069 [€ 1,618,344], IFNβ -1b: € 826,633 [€ 1,647,745], GA: € 823,438 [€ 1,649,961], 
IFNβ -1a-IM: € 820,516 [€ 1,645,472], and BSC: € 788,932 [€ 1,626,554]. Respective QALYs 
were 6.55 [5.44], 6.27 [5.13], 6.15 [4.99], 6.05 [4.88], 6.04 [4.87], and 5.79 [4.60]. From 
the payer [societal] perspective, incremental cost per QALY gained of teriflunomide 
was € 13,089 [dominant] relative to BSC, and teriflunomide dominated other first-
line DMTs. Teriflunomide had 83% [per-patient expected value of perfect informa-
tion, EVPI € 241], 98% [EVPI € 22], and 100% [EVPI € 0] cost-effectiveness probability 
with € 0, € 10,000, and € 20,000 per additional QALY, respectively. ConClusions: 
Cost-effectiveness analyses of first-line DMTs compared to BSC showed that teri-
flunomide provided lowest cost and highest number of QALYs and was therefore 
dominant over IFNβ s and GA for Finnish RRMS patients.
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Cost-effeCtiveNess moDel resUlts of iNtrAtheCAl BAClofeN therAPy 
ComPAreD to CoNveNtioNAl meDiCAl mANAgemeNt iN PAtieNts with 
NoN-foCAl DisABliNg sPAstiCity who Are resistANt or iNtolerANt to 
orAl therAPy At the iNstitUt gUttmANN
Slof J.1, Serrano D.2, Álvarez M.3, Álvarez López-Dóriga M.3, Marqués T.4, Benito J.4, Vidal J.4
1Universitat Autònoma de Barcelona, Bellaterra, Spain, 2Autonomous Consultant, Barbera del 
Valles, Spain, 3Medtronic Ibérica, S.A., Madrid, Spain, 4Institut Guttmann, Barcelona, Spain
objeCtives: To estimate the cost-effectiveness of intrathecal baclofen ther-
apy (ITB) against conventional medical management (CMM) in non-focal 
disabling spasticity (N-FDS) patients who are resistant or intolerant to oral ther-
apy. Methods: A markov model was developed to estimate clinical and economic 
outcomes for patients treated with ITB or CMM. Treatment effects, patients´ base-
line characteristics, resource utilization and health utility values were taken from 
the EPICE study. The model was built in accordance with the Institut Guttmann´s 
clinical practice, a reference center in Spain. Unit costs were obtained from the 
cited center. The analysis was conducted from the Institut Guttmann´s perspec-
tive over a lifetime horizon with direct medical costs (2013) and outcomes dis-
counted at 3%. Uncertainty was assessed through univariate and multivariate 
sensitivity analysis (SA). Results: When comparing ITB with CMM, the model 
estimates ITB would increase remaining lifetime costs by € 35,605 and result in a 
QALY gain of 1.06; thus showing an incremental cost-effectiveness ratio (ICER) of 
€ 33,619 per QALY gained. SA reflecting the most current clinical practice at the 
Institut Guttmann (where now a new catheter, associated with an 80% reduction 
in adverse events, is used) showed an ICER of € 27,805 per QALY gained. ICER 
results were also sensitive to changes in the post-operation hospitalization period, 
baclofen dose titration management, pump battery life, and health utility val-
ues. ConClusions: The present evaluation results in an ICER of ITB against CMM, 
in the treatment of N-FDS patients who are resistant or intolerant to oral therapy 
at the Institut Guttmann, close to a willingness-to-pay threshold of € 30,000 per 
states: Expanded Disability Status Scale (EDSS) 0-9 for patients with RRMS and 
secondary progressive multiple sclerosis (SPMS), respectively, and death (EDSS10). 
Total treatment costs, quality-adjusted life-years (QALYs) gained and incremental 
cost-effectiveness ratios (ICERs) were calculated from the Dutch societal perspec-
tive. Baseline demographics; transition probabilities; treatment-specific relative 
risks; and utility values were obtained from published literature. Health resource 
use was based on the products’ SmPCs. Unit costs were based on national tar-
iffs and published data. A base case analysis considered the direct and indirect 
costs of treatment. To test the robustness of the results, univariate and probabil-
istic sensitivity analyses (PSA) were performed. Results: Total treatment costs 
of glatiramer acetate were lower versus teriflunomide, interferon-beta-1a 44mcg, 
30mcg, fingolimod, natalizumab, dimethyl fumarate and alemtuzumab; and higher 
versus interferon-beta-1a 22mcg, interferon-beta-1b, and BSC. Glatiramer acetate 
dominated interferon-beta-1a 44mcg and 30mcg, and was cost-effective versus 
other comparators at a willingness-to-pay threshold of € 20,000/QALY. The PSA 
indicated these results were robust. Univariate analysis showed that relative risks 
of disease progression and drug costs were the most influential model param-
eters. ConClusions: In the Netherlands, glatiramer acetate is a cost-effective 
treatment versus a number of other treatments indicated in multiple sclerosis, 
and results proved robust.
Pnd49
exPeCteD vAlUe of PArtiAl PerfeCt iNformAtioN for the DisABility 
ProgressioN effiCACy of teriflUNomiDe AND fiNgolimoD iN the 
treAtmeNt of relAPsiNg-remittiNg mUltiPle sClerosis
Maruszczak M.1, Kusel J.1, Adlard N.2
1Costello Medical Consulting Ltd., Cambridge, UK, 2Novartis Pharmaceuticals UK Limited,  
Surrey, UK
objeCtives: To calculate the expected value of partial perfect information (EVPPI) 
of the disability progression efficacy for teriflunomide and fingolimod in relapsing-
remitting multiple sclerosis (RRMS) and investigate the potential differences between 
these two disease modifying therapies (DMTs). Methods: A cohort Markov model 
based on the ScHARR model structure was developed from the UK NHS perspective, 
which allows the cost-effectiveness of the DMTs to be calculated and also has the 
additional ability to calculate the EVPPIs for progression efficacies. The evaluated 
intervention consists of beta-interferons followed by fingolimod. The comparator 
treatment includes beta-interferon therapy followed by teriflunomide. The EVPPIs 
for both drugs were calculated and compared. Results: The EVPPIs varied substan-
tially depending on the evaluated drug and the specific willingness-to-pay (WTP). 
Although both EVPPI curves had a similar shape, the curve for teriflunomide had an 
EVPPI equal or larger compared to fingolimod’s curve for every WTP value. At a WTP 
of £30,000 per QALY, the EVPPI per patient of teriflunomide and fingolimod were 
£252 and £50, respectively. In the sensitivity analysis, where the uncertainty around 
the estimate of teriflunomide progression efficacy was artificially lowered to that of 
fingolimod, the divergence between the EVPPI curves was reduced substantially, con-
firming that the uncertainty around teriflunomide progression efficacy is driving its 
higher EVPPI. ConClusions: Higher EVPPI estimates of teriflunomide indicate that 
the precise knowledge of the disability progression efficacy of teriflunomide would 
be considerably more valuable to the decision maker than that of fingolimod. One 
of the main factors affecting larger EVPPI of teriflunomide’s progression efficacy is a 
higher uncertainty concerning effects of teriflunomide. There are, however, many data 
limitations and uncertainties within the DMT modelling. Additionally, the expected 
value of sample information analysis (EVSI) would be required in order to evaluate 
more precisely the cost-effectiveness of additional clinical trials.
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Cost-miNimisAtioN ANAlysis of ColistimethAte soDiUm iN serBiA- off 
lABel Use APProACh
Djordjevic J.1, Mitrovic M.1, Marinkovic V.1, Tasic L.2, Krajnovic D.2
1Alvogen Pharma doo Serbia, Belgrade, Serbia and Montenegro, 2University of Belgrade – Faculty 
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objeCtives: Colistimethate sodium (Colistin) is an old, “forgotten” antibiotics 
revived due to multidrug-resistant Gram-negative bacteria in nosocomial infec-
tions. In many countries, both – intravenous and inhalational administrations of 
Colistin have marketing authorisation. In Serbia, Colistin is registered only for 
intravenous administration. Therefore, inhalational administration of Colistin in 
treatment for cystic fibrosis is considered as off label use. AiM: The purpose of 
this study was to assess benefits of Colistin off label use, currently available in 
Serbia, for treatment for cystic fibrosis. Methods: Data collected from a review 
of the literature (Pubmed searching key word off label, Colistin, Tobramycine, cost 
minimisation) and data from Health Insurance Fond of Republic Serbia (2014) 
were used to perform a cost-minimisation analysis comparing DDD in inhalation 
administration of Colistin with Tobramycin (official methodology in Serbia for drug 
reimbursement Listing). Results: Both, Colistin and Tobramycine are effective 
in cystic fibrosis treatment. The cost of treatment per patient per year in Serbia is 
3 616,00 Euro for Colistin and 5 950,00 Euro for Tobramycin. Total savings per year 
for 200 registered patients in Serbia could be 466 857,00 Euro. ConClusions: 
Given cost-minimisation analysis justified the treatment with Colistin as cost 
saving therapeutic alternative to Tobramycin for cystic fibrosis patients in Serbia. 
The lack of guidelines and principles regarding off label medicine use in health 
care policy and decision making in Serbia was evidently an obstacle for better 
patients care.
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heAlth CAre UtilizAtioN AND Costs of meDiCAiD ProgrAm serviCes 
for PAtieNts DiAgNoseD with mUltiPle sClerosis
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Ann Arbor, MI, USA
